Protocol for a double-blind placebocontrolled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults

Ivan Koychev; Amanda I Adler; Paul   Edison; Brian D. Tom; Joanne E   Milton; Joe  Butchart; Adam Hampshire; Charles   Marshall; E J Coulthard; Henrik Zetterberg; Peter Hellyer; Francesca K Cormack; Benjamin R Underwood; Catherine J Mummery; Rury R.  Holman

Protocol for a double-blind placebocontrolled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults

Ivan Koychev^*
, Amanda I Adler
, Paul Edison
, Brian D. Tom
, Joanne E Milton
, Joe Butchart
, Adam Hampshire
, Charles Marshall
, E J Coulthard
, Henrik Zetterberg
, Peter Hellyer
, Francesca K Cormack
, Benjamin R Underwood
, Catherine J Mummery
, Rury R. Holman

^*Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), currently marketed for type 2 diabetes and obesity, may offer novel mechanisms to delay or prevent neurotoxicity associated with Alzheimer’s disease (AD). The impact of semaglutide in amyloid positivity (ISAP) trial is investigating whether the GLP-1 RA semaglutide reduces accumulation in the brain of cortical tau protein and neuroinflammation in individuals with preclinical/prodromal AD.

Original language	English
Journal	BMJ
Publication status	Published - 22 Jun 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

https://bmjopen.bmj.com/content/14/6/e081401.full

Handle.net

Persistent link

Cite this

Koychev, I., Adler, A. I., Edison, P., Tom, B. D., Milton, J. E., Butchart, J., Hampshire, A., Marshall, C., Coulthard, E. J., Zetterberg, H., Hellyer, P., Cormack, F. K., Underwood, B. R., Mummery, C. J., & Holman, R. R. (2024). Protocol for a double-blind placebocontrolled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults. BMJ. https://bmjopen.bmj.com/content/14/6/e081401.full

@article{d25ab741e58a47f0bd3121ab4c037592,

title = "Protocol for a double-blind placebocontrolled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults",

abstract = "Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), currently marketed for type 2 diabetes and obesity, may offer novel mechanisms to delay or prevent neurotoxicity associated with Alzheimer{\textquoteright}s disease (AD). The impact of semaglutide in amyloid positivity (ISAP) trial is investigating whether the GLP-1 RA semaglutide reduces accumulation in the brain of cortical tau protein and neuroinflammation in individuals with preclinical/prodromal AD.",

author = "Ivan Koychev and Adler, \{Amanda I\} and Paul Edison and Tom, \{Brian D.\} and Milton, \{Joanne E\} and Joe Butchart and Adam Hampshire and Charles Marshall and Coulthard, \{E J\} and Henrik Zetterberg and Peter Hellyer and Cormack, \{Francesca K\} and Underwood, \{Benjamin R\} and Mummery, \{Catherine J\} and Holman, \{Rury R.\}",

year = "2024",

month = jun,

day = "22",

language = "English",

journal = "BMJ",

issn = "0959-8138",

publisher = "BMJ Publishing Group",

}

Koychev, I, Adler, AI, Edison, P, Tom, BD, Milton, JE, Butchart, J, Hampshire, A, Marshall, C, Coulthard, EJ, Zetterberg, H, Hellyer, P, Cormack, FK, Underwood, BR, Mummery, CJ & Holman, RR 2024, 'Protocol for a double-blind placebocontrolled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults', BMJ. <https://bmjopen.bmj.com/content/14/6/e081401.full>

TY - JOUR

T1 - Protocol for a double-blind placebocontrolled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults

AU - Koychev, Ivan

AU - Adler, Amanda I

AU - Edison, Paul

AU - Tom, Brian D.

AU - Milton, Joanne E

AU - Butchart, Joe

AU - Hampshire, Adam

AU - Marshall, Charles

AU - Coulthard, E J

AU - Zetterberg, Henrik

AU - Hellyer, Peter

AU - Cormack, Francesca K

AU - Underwood, Benjamin R

AU - Mummery, Catherine J

AU - Holman, Rury R.

PY - 2024/6/22

Y1 - 2024/6/22

N2 - Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), currently marketed for type 2 diabetes and obesity, may offer novel mechanisms to delay or prevent neurotoxicity associated with Alzheimer’s disease (AD). The impact of semaglutide in amyloid positivity (ISAP) trial is investigating whether the GLP-1 RA semaglutide reduces accumulation in the brain of cortical tau protein and neuroinflammation in individuals with preclinical/prodromal AD.

AB - Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), currently marketed for type 2 diabetes and obesity, may offer novel mechanisms to delay or prevent neurotoxicity associated with Alzheimer’s disease (AD). The impact of semaglutide in amyloid positivity (ISAP) trial is investigating whether the GLP-1 RA semaglutide reduces accumulation in the brain of cortical tau protein and neuroinflammation in individuals with preclinical/prodromal AD.

M3 - Article (Academic Journal)

SN - 0959-8138

JO - BMJ

JF - BMJ

ER -

Protocol for a double-blind placebocontrolled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults

Abstract

UN SDGs

Access to Document

Handle.net

Fingerprint

Cite this